Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 704 posts found.

roche__tree

Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma

November 25, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News

Working Life Interview: Alison Muir, Oncology Product Strategy Director at Roche

November 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Working Life, feature, pharma

You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …

Feature
roche

Roche’s risdiplam hits main goal in spinal muscular atrophy type 2 or 3

November 11, 2019
Research and Development, Sales and Marketing Roche, pharma, risdiplam, spinal muscular atrophy

Roche has lifted the curtain on new data which shows that its investigational survival motor neuron-2 (SMN2) splicing modifier risdiplam …

News

Roche terminates Duchenne muscular dystrophy candidate due to poor clinical outlook

November 8, 2019
Medical Communications, Research and Development Duchenne Muscular Dystrophy, Roche, pharma

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …

News
rocheshanghai

Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma

October 21, 2019
Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq

New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …

News
genentech_web

FDA greenlights Genentech’s Xofluza for acute, uncomplicated influenza

October 18, 2019
Medical Communications FDA, Genetech, Roche, US, Xofluza, flu, pharma

Roche subsidiary Genentech has announced that its polymerase acidic endonuclease inhibitor Xofluza (baloxavir marboxil) has been awarded FDA approval in …

News
roche__tree

Roche’s Phase 3 Pemphix trial smashes primary endpoint for pemphigus vulgaris

October 14, 2019
Research and Development, Sales and Marketing MabThera, Rituxan, Roche, pharma

Roche has revealed new Phase 3 data demonstrating that its MabThera/Rituxan (rituximab) therapy Pemphix met its primary endpoint in the …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
roche__tree

Roche’s Tecentriq plus chemo shows promise in first-line, advanced bladder cancer

October 1, 2019
Manufacturing and Production, Research and Development Cancer, ESMO 2019, Roche, breast cancer, pharma, tecentriq

Roche has revealed data from an interim analysis of its immunotherapy Tecentriq (atezolizumab) at the 2019 European Society for Medical …

News
shutterstock

The world needs a better plan for cancer survival by 2030

September 30, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Roche, UN General Assembly, United Nations, feature, opinion, pharma

Beginning on 24 September, the UN will convene in New York for its annual General Assermbly. Dr Christian Rommel, Roche´s …

Feature

Roche secures US paediatric approval for Rituxan in two rare forms of vasculitis

September 30, 2019
Sales and Marketing MabThera, Rituxan, Roche, pharma, vasculitis

Roche has revealed that Rituxan (rituximab), also known as MabThera, has been awarded US approval from the FDA in combination …

News
roche

Roche bags FDA Breakthrough for Gazyva in lupus nephritis

September 18, 2019
Research and Development FDA, Gazyva, Roche, lupus nephritis

The US FDA has granted Breakthrough Therapy Designation to Gazyva (obinutuzumab) for adults with lupus nephritis. The win comes on …

News

Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis

September 13, 2019
Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …

News
images

Roche’s satralizumab succeeds in second positive study in rare CNS disease

September 12, 2019
Research and Development NMOSD, Roche, satralizumab

In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for …

News

Roche celebrates European approval of Tecentriq combo in first-line lung cancer

September 6, 2019
Medical Communications, Sales and Marketing Cancer, Europe, Roche, lung cancer, pharma, tecentriq

Roche has confirmed that its immunotherapy Tecentriq (atezolizumab) has been approved in Europe in combination with chemotherapy (carboplatin and etoposide) …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024